NBCC Chief Programs Officer Michelle Tregear in ASCO Daily:
When a therapy becomes standard of care, patients tend to assume it will extend survival or improve quality of life, even when evidence for those outcomes may be limited or unclear. Even when quality-of-life and patient-reported outcomes are collected, they are often published long after efficacy results, limiting their usefulness in real-time decision-making.
Tregear will be part of an education session at this year’s ASCO Annual Meeting, during which speakers will offer multiple perspectives on centering oncology on what matters most to patients, highlighting clinical trials endpoints and health systems organization:
The Education Session reflects a broader movement in oncology, including efforts by the National Breast Cancer Coalition and Common Sense Oncology, to raise the bar on how we define benefit. We’re not questioning progress. We’re asking how to ensure that it’s meaningful to patients. This conversation will resonate with anyone involved in designing trials, interpreting data, or caring for patients.
